What are the potential benefits of Liraglutide?

FDA-approved for T2D (Victoza) and obesity/weight management (Saxenda). ~8% average weight loss in obesity trials. 13% reduction in cardiovascular events (LEADER trial). HbA1c reduction ~1.5% in T2D. Kidney disease protection in diabetic patients. Established long-term cardiovascular safety data (3 years). Also studied in non-alcoholic fatty liver disease

What compounds work synergistically with Liraglutide?

Liraglutide has been studied alongside Metformin, SGLT-2 inhibitors, Exercise for potential synergistic effects.

Liraglutide — Mechanism, Benefits, Research & Synergies

Overview

Liraglutide is an FDA-approved GLP-1 receptor agonist peptide with 97% structural homology to human GLP-1, modified with a fatty acid side chain enabling self-aggregation and albumin binding for extended half-life (~13 hours). Approved for type 2 diabetes (Victoza, 2010) and obesity (Saxenda, 2014), it was the pioneering GLP-1 agonist demonstrating meaningful cardiovascular risk reduction (LEADER trial: 13% reduction in MACE). Its relatively shorter half-life than semaglutide requires daily dosing, but it established the GLP-1 class as cardiovascular-protective weight loss agents.

Mechanism of Action

Liraglutide activates GLP-1R on pancreatic beta-cells (glucose-dependent insulin secretion), alpha-cells (glucagon suppression), brain (hypothalamic satiety centers, dopamine reward pathways), heart (direct cardioprotection via RISK pathway), and kidney (GFR preservation). The central effects on arcuate nucleus reduce food intake and energy intake, contributing to 8% average weight loss in clinical trials. Cardioprotection involves reduced inflammation, improved endothelial function, and direct myocardial GLP-1R signaling.

Potential Benefits

FDA-approved for T2D (Victoza) and obesity/weight management (Saxenda)
~8% average weight loss in obesity trials
13% reduction in cardiovascular events (LEADER trial)
HbA1c reduction ~1.5% in T2D
Kidney disease protection in diabetic patients
Established long-term cardiovascular safety data (3 years)
Also studied in non-alcoholic fatty liver disease

Research Dosage Notes

The following reflects doses used in published research studies. This is not medical advice.

T2D (Victoza): 0.6-1.8 mg/day subcutaneous. Obesity (Saxenda): 0.6 mg escalating to 3 mg/day subcutaneous. Daily injections required.

Amino Acid Sequence

34-amino acid GLP-1 analog with C16 fatty acid at Lys26 via glutamic acid spacer

Side Effects & Safety

Nausea, vomiting, diarrhea (dose-dependent)
Pancreatitis risk (rare)
Gallbladder disease
Thyroid C-cell tumors in animal models
Injection site reactions
Tachycardia

Synergistic Compounds

The following compounds have been studied alongside Liraglutide for potential complementary or synergistic effects:

MetforminSGLT-2 inhibitorsExercise

Learn More

Beginner's GuideNew to peptides? Start here Stacking GuideSynergistic combinations Administration RoutesSubQ, IM, oral, nasal & more Reconstitution CalculatorCalculate exact dosing Peptides vs SARMsFull comparison How Peptides Are MadeSPPS, purification & QC

References & Further Reading

[object Object]

Quick Facts

Molecular Weight	3751.20 g/mol
Research Status	FDA-approved (2010 T2D, 2014 obesity). Extensive post-marketing safety data. Primarily being replaced by semaglutide/tirzepatide for new patients due to superior efficacy of newer agents.

More Peptides in This Category

Tesamorelin AOD-9604 Fragment 176-191 Kisspeptin Follistatin-344 MOTS-c

Liraglutide